It has recently been demonstrated that early exposure to anti-TNF therapy is associated with substantially reduced PD incidence in individuals with IBD, highlighting systemic inflammation as a potential link between these two diseases (Peter et al., 2018). Here, TNF is linked to inflammatory bowel disease.